• Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (PubMed=19654294).
  
• Mutation; HGNC; HGNC:7765; NF1; Simple; p.Arg160Trp (c.478A>T); ClinVar=VCV000412204; Zygosity=Homozygous (CelloPub=CLPUB00667; DepMap=ACH-001632).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Homozygous (CelloPub=CLPUB00667; PubMed=25230021; PubMed=28273451; DepMap=ACH-001632).
  

PubMed=3583449; DOI=10.1002/ijc.2910390607
Wolf C.R., Hayward I.P., Lawrie S.S., Buckton K., McIntyre M.A., Adams D.J., Lewis A.D., Scott A.R.R., Smyth J.F.
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.
Int. J. Cancer 39:695-702(1987)

PubMed=3167863
Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Cancer Res. 48:6166-6172(1988)

PubMed=1348364; DOI=10.1073/pnas.89.7.3070; PMCID=PMC48805
Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C., Anderson M.E.
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=9041185
Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Cancer Res. 57:850-856(1997)

PubMed=19654294; DOI=10.1158/0008-5472.CAN-09-1178; PMCID=PMC2754824
Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J., Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T.
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Cancer Res. 69:6381-6386(2009)

PubMed=20581869; DOI=10.1038/onc.2010.245; PMCID=PMC2933510
Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T.J., Temple J., Langdon S.P., Huntsman D.G., Brenton J.D.
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Oncogene 29:4905-4913(2010)

PubMed=22183581; DOI=10.1002/path.3980
Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J., Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
J. Pathol. 226:703-712(2012)

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821
Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer Discov. 2:56-67(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516
Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Gynecol. Oncol. 142:332-340(2016)

PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645.1-12645.14(2016)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

CLPUB00667
Lisio M.-A.
Evaluation of platinum-sensitivity in a cell line model of high grade serous ovarian cancer and the induction of resistance from a chemo- sensitive cell line through the repopulation of cells following short-term cisplatin treatment.
Thesis PhD (2019); McGill University Montreal; Montreal; Canada

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471; PMCID=PMC8714940
Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J., Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N., Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J., Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D., Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B., Wang P., Birrer M.J., Paulovich A.G.
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Cell Rep. Med. 2:100471.1-100471.32(2021)